

PATENT COOPERATION TREATY

Subject to PTA? ☒ YES / ☐ NO
per docket/ECB

File Folder	2/24/02	<input type="checkbox"/>
ECB	3/22/02	<input type="checkbox"/>
Docket Entry	(2)	<input checked="" type="checkbox"/>
Docket Cross Off		<input checked="" type="checkbox"/>
Order Copies		<input type="checkbox"/>
Annuities		<input type="checkbox"/>
Confirmation		<input type="checkbox"/>

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:
WOLF, GREENFIELD & SACKS, P.C.
Attn. Lockhart, Helen C.
600 Atlantic Avenue
Boston, Massachusetts 02210
UNITED STATES OF AMERICA

DOCKETED
FEB 4 2002

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

Applicant's or agent's file reference M0656/7063W0	Date of mailing (day/month/year) 22/01/2002
International application No. PCT/US 01/ 07464	International filing date (day/month/year) 08/03/2001
Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY	

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.


☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after **18 months** from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within **19 months** from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within **20 months** from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Catherine Humbert
--	--

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions, respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments and any accompanying statement, under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the time of filing the amendments (and any statement) with the International Bureau, also file with the International Preliminary Examining Authority a copy of such amendments (and of any statement) and, where required, a translation of such amendments for the procedure before that Authority (see Rules 55.3(a) and 62.2, first sentence). For further information, see the Notes to the demand form (PCT/IPEA/401).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference M0656/7063W0	FOR FURTHER ACTION <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. PCT/US 01/ 07464	International filing date (day/month/year) 08/03/2001	(Earliest) Priority Date (day/month/year) 08/03/2000
Applicant MASSACHUSETTS INSTITUTE OF TECHNOLOGY		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 8 sheets.
☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☒ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

8
☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/07464

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-22, insofar as in vivo methods are concerned, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-27

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-27

Methods for preventing proliferation of a tumor or for preventing tumor cell metastasis, comprising exposing a tumor cell to heparinase III, either native or modified.

Methods for preparing therapeutic agents, i.e., HLGAG fragments, for tumor treatment, comprising isolating of a portion of a tumor, treating it with heparinase III to produce HLGAG fragments, and isolating HLGAG fragments, possibly further comprising determining the sequence of the HLGAG fragments.

Methods for treating a subject having a tumor, comprising administering to the subject a therapeutic, synthetic or isolated HLGAG fragment, identified or produced when the tumor is contacted with heparinase III.

Pharmaceutical compositions comprising heparinase III, either native or modified, for preventing metastasis of a tumor cell, e.g., with a targeting molecule for targeting heparinase III to the tumor, the targeting molecule being a compound which binds specifically to an antigen on the surface of a tumor cell, or with an anti-cancer compound.

Pharmaceutical compositions comprising a therapeutic HLGAG fragment for preventing metastasis of a tumor cell, e.g., with an anti-cancer compound.

2. Claims: 28-49

A substantially pure heparinase III comprising a polypeptide according to SEQ ID NO:2, or having conservative substitutions thereof within residues non-essential to enzymatic function, wherein at least one His residue from the group of His36, His105, His110, His 139, His152, His 225, His234, His241, His424, His469 and His539 has been substituted with an Ala, Ser, Tyr, Thr or Lys residue.

A substantially pure heparinase III having a modified product profile which is at least 10% different than the product profile of native heparinase III.

A substantially pure heparinase III that can cleave a heparan sulfate having a modified k-cat value which is at least 10% different than a k-cat value of native heparinase III.

A pharmaceutical preparation comprising a heparinase III as said.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

An immobilized substantially pure modified heparinase III comprising a modified heparinase III as said and a solid support.

A method of specifically cleaving a HLGAG comprising contacting a HLGAG with a modified heparinase III as said, e.g., wherein the heparinase III is administered to subject in need for inhibiting angiogenesis, or wherein the heparinase is administered to a tumor, or wherein the heparinase III is administered in a polymeric delivery device or in a vehicle for injection or in a vehicle for topical application (e.g., to the eye), or wherein the method is a method for sequencing HLGAG fragments.

3. Claims: 50-54

Methods for treating or preventing a subject having a cancer or at risk of developing a cancer, comprising administering a therapeutic HLGAG fragment, e.g., a composition of HLGAG fragments wherein at least 50%, 75% or 90% of the HLGAG fragments are di- or tri-sulfated disaccharides, or wherein the therapeutic HLGAG fragment is free of mono- or unsulfated disaccharides.

4. Claims: 55-60

A method for preparing LMWH comprising contacting an HLGAG sample with a modified heparinase III molecule to produce LMWH.

A composition comprising LMWH produced by contacting an HLGAG sample with a modified heparinase III. Methods of treating or preventing, e.g., of a disorder associated with coagulation, or of a tumor, or of psoriasis, or of neovascularization, comprising administering to a subject a composition as said.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/07464

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/60 C12N9/88 C12P19/26 A61K38/51 A61K31/715
C08B37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 01648 A (IBEX TECHNOLOGIES R AND D INC ;ZIMMERMANN JOSEPH (US); VLODAVSKY I) 25 January 1996 (1996-01-25) the whole document page 3, line 23 -page 4, line 5 page 9, line 17 -page 10, line 30 examples 3-5,9-16 claims 1-28	1-27
X	NATKE B ET AL.: "Heparinase treatment of bovine smooth muscle cells inhibits fibroblast growth factor-2 binding to fibroblast growth factor receptor but not FGF-2 mediated cellular proliferation" ANGIOGENESIS, vol. 3, no. 3, 1999, pages 249-257, XP001030515 abstract	1-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 2001

Date of mailing of the international search report

22. 01. 2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

van de Kamp, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MURPHY P R ET AL.: "Basic fibroblast growth factor binding and processing by human glioma cells." MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 114, no. 1-2, 1995, pages 193-203, XP001030507 ISSN: 0303-7207 abstract ---	1-17, 23-27
X	WO 95 13830 A (MASSACHUSETTS INST TECHNOLOGY ;CHILDRENS MEDICAL CENTER (US)) 26 May 1995 (1995-05-26) the whole document page 9, line 29 -page 10, line 33 page 13, line 7 -page 40, line 18 claims 1-21 ---	1-17, 23-27
X	WO 94 21689 A (CANCER RES CAMPAIGN TECH ;LYON MALCOLM (GB); GALLAGHER JOHN THOMAS) 29 September 1994 (1994-09-29) the whole document page 3, line 21 -page 10, line 17 table 1 claims 1-33 ---	18-27
X	WO 93 19096 A (CANCER RES CAMPAIGN TECH) 30 September 1993 (1993-09-30) the whole document page 7, line 32 -page 15, line 27 tables 1,2 claims 1-40 ---	18-27
X	WO 93 05167 A (CHILDRENS MEDICAL CENTER) 18 March 1993 (1993-03-18) page 3, line 1 -page 4, line 3 page 11, line 25 -page 16, line 33 figure 3 ---	18-27
A	WO 92 01003 A (UNIV TEXAS) 23 January 1992 (1992-01-23) the whole document ---	18-27
A	PADERA R ET AL.: "FGF-2/fibroblast growth factor receptor/heparin-like glycosaminoglycan interactions: A compensation model for FGF-2 signaling." FASEB JOURNAL, vol. 13, no. 13, October 1999 (1999-10), pages 1677-1687, XP002179630 ISSN: 0892-6638 the whole document --- -/--	18-27

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/07464

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>VENKATARAMAN G: "Sequencing complex polysaccharides" SCIENCE, vol. 286, 15 October 1999 (1999-10-15), pages 537-542, XP002179570 cited in the application the whole document</p> <p>---</p>	19
A	<p>GODAVARTI R ET AL.: "Heparinase III from Flavobacterium heparinum: Cloning and recombinant expression in Escherichia coli." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 225, no. 3, 1996, pages 751-758, XP002179572 ISSN: 0006-291X cited in the application the whole document abstract page 751, line 15 -page 752, line 2 page 757, line 42-50</p> <p>---</p>	
A	<p>WO 94 12618 A (MASSACHUSETTS INST TECHNOLOGY ;UNIV IOWA RES FOUND (US)) 9 June 1994 (1994-06-09) the whole document</p> <p>---</p>	
A	<p>LINHARDT R J ET AL.: "Examination of the substrate specificity of heparin and heparan sulfate lyases" BIOCHEMISTRY, vol. 29, no. 10, 1990, pages 2611-2617, XP002028479 ISSN: 0006-2960 cited in the application abstract page 2616, left-hand column, line 30 -right-hand column, line 15</p> <p>---</p>	
A	<p>ERNST S ET AL.: "Enzymatic degradation of glycosaminoglycans." CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 30, no. 5, 1995, pages 387-444, XP001030549 ISSN: 1040-9238 cited in the application abstract</p> <p>---</p> <p style="text-align: center;">-/--</p>	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	AMEER G A ET AL.: "A new approach to regional heparinization: Design and development of a novel immobilized heparinase device." BLOOD PURIFICATION. MEETING INFO.: THIRD INTERNATIONAL CONFERENCE ON CONTINUOUS RENAL REPLACEMENT THERAPIES SAN DIEGO, CALIFORNIA, USA MARCH 5-7, 1998, vol. 16, no. 2, 5 March 1998 (1998-03-05), pages 107-108, XP001032809 abstract ---	
A	EP 0 244 236 A (NOVO INDUSTRI AS) 4 November 1987 (1987-11-04) the whole document ---	
A	EP 0 394 971 A (KABIVITRUM AB ; HARVARD COLLEGE (US)) 31 October 1990 (1990-10-31) the whole document ---	
T	BERRY D ET AL.: "Distinct heparan sulfate glycosaminoglycans are responsible for mediating fibroblast growth factor-2 biological activity through different fibroblast growth factor receptors" FASEB JOURNAL ON LINE, 6 April 2001 (2001-04-06), XP002179629 the whole document -----	18-27

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/07464

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9601648	A	25-01-1996	US 5997863 A AU 707007 B2 AU 3094995 A CA 2194370 A1 EP 0769961 A1 JP 10506609 T WO 9601648 A1	07-12-1999 01-07-1999 09-02-1996 25-01-1996 02-05-1997 30-06-1998 25-01-1996
WO 9513830	A	26-05-1995	CA 2176934 A1 EP 0726773 A1 JP 9508892 T WO 9513830 A1 US 5567417 A	26-05-1995 21-08-1996 09-09-1997 26-05-1995 22-10-1996
WO 9421689	A	29-09-1994	AU 6287594 A CA 2136531 A1 EP 0642533 A1 WO 9421689 A1 JP 7507596 T	11-10-1994 29-09-1994 15-03-1995 29-09-1994 24-08-1995
WO 9319096	A	30-09-1993	AU 3763293 A CA 2132750 A1 EP 0632818 A1 WO 9319096 A1 GB 2265905 A ,B JP 7505179 T	21-10-1993 30-09-1993 11-01-1995 30-09-1993 13-10-1993 08-06-1995
WO 9305167	A	18-03-1993	AU 2561792 A US 5486599 A WO 9305167 A1	05-04-1993 23-01-1996 18-03-1993
WO 9201003	A	23-01-1992	US 5262403 A AU 8306791 A WO 9201003 A1	16-11-1993 04-02-1992 23-01-1992
WO 9412618	A	09-06-1994	US 5389539 A CA 2150263 A1 EP 0670892 A1 JP 8505767 T WO 9412618 A1 US 5569600 A	14-02-1995 09-06-1994 13-09-1995 25-06-1996 09-06-1994 29-10-1996
EP 0244236	A	04-11-1987	AU 588102 B2 AU 7225587 A CA 1334081 A1 DK 217187 A ,B, EP 0244236 A2 FI 871910 A ,B, JP 1835416 C JP 5042919 B JP 62283103 A NO 871783 A ,B, US 5106734 A	07-09-1989 05-11-1987 24-01-1995 31-10-1987 04-11-1987 31-10-1987 11-04-1994 30-06-1993 09-12-1987 02-11-1987 21-04-1992
EP 0394971	A	31-10-1990	AU 5445290 A CA 2053883 A1 WO 9012580 A1 EP 0394971 A1	16-11-1990 25-10-1990 01-11-1990 31-10-1990

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/07464

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0394971	A	HU 59828 A2	28-07-1992
		NO 914133 A	21-10-1991
		PT 93847 A	20-11-1990
